Literature DB >> 16841094

Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.

Christian Hafner1, Johanna M M van Oers, Thomas Vogt, Michael Landthaler, Robert Stoehr, Hagen Blaszyk, Ferdinand Hofstaedter, Ellen C Zwarthoff, Arndt Hartmann.   

Abstract

Epidermal nevi are common congenital skin lesions with an incidence of 1 in 1,000 people; however, their genetic basis remains elusive. Germline mutations of the FGF receptor 3 (FGFR3) cause autosomal dominant skeletal disorders such as achondroplasia and thanatophoric dysplasia, which can be associated with acanthosis nigricans of the skin. Acanthosis nigricans and common epidermal nevi of the nonorganoid, nonepidermolytic type share some clinical and histological features. We used a SNaPshot multiplex assay to screen 39 epidermal nevi of this type of 33 patients for 11 activating FGFR3 point mutations. In addition, exon 19 of FGFR3 was directly sequenced. We identified activating FGFR3 mutations, almost exclusively at codon 248 (R248C), in 11 of 33 (33%) patients with nonorganoid, nonepidermolytic epidermal nevi. In 4 of these cases, samples from adjacent histologically normal skin could be analyzed, and FGFR3 mutations were found to be absent. Our results suggest that a large proportion of epidermal nevi are caused by a mosaicism of activating FGFR3 mutations in the human epidermis, secondary to a postzygotic mutation in early embryonic development. The R248C mutation appears to be a hot spot for FGFR3 mutations in epidermal nevi.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841094      PMCID: PMC1501112          DOI: 10.1172/JCI28163

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.

Authors:  Bas W G van Rhijn; Angela A G van Tilborg; Irene Lurkin; Jacky Bonaventure; Annie de Vries; Jean-Paul Thiery; Theodorus H van der Kwast; Ellen C Zwarthoff; Francois Radvanyi
Journal:  Eur J Hum Genet       Date:  2002-12       Impact factor: 4.246

2.  Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.

Authors:  Rivka Adar; Efrat Monsonego-Ornan; Pe'er David; Avner Yayon
Journal:  J Bone Miner Res       Date:  2002-05       Impact factor: 6.741

3.  The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

Authors:  T Kimura; H Suzuki; T Ohashi; K Asano; H Kiyota; Y Eto
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

4.  FGFR3 dimer stabilization due to a single amino acid pathogenic mutation.

Authors:  Edwin Li; Min You; Kalina Hristova
Journal:  J Mol Biol       Date:  2005-12-12       Impact factor: 5.469

5.  Frequent FGFR3 mutations in urothelial papilloma.

Authors:  Bas W G van Rhijn; Rodolfo Montironi; Ellen C Zwarthoff; Adriaan C Jöbsis; Theo H van der Kwast
Journal:  J Pathol       Date:  2002-10       Impact factor: 7.996

6.  Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia.

Authors:  Valentine J Hyland; Stephen P Robertson; Simon Flanagan; Ravi Savarirayan; Tony Roscioli; John Masel; Mark Hayes; Ian A Glass
Journal:  Am J Med Genet A       Date:  2003-07-15       Impact factor: 2.802

7.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.

Authors:  Bas W G van Rhijn; André N Vis; Theo H van der Kwast; Wim J Kirkels; François Radvanyi; Engelbert C M Ooms; Dominique K Chopin; Egbert R Boevé; Adriaan C Jöbsis; Ellen C Zwarthoff
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

8.  Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.

Authors:  Joshua L Paterson; Zhihua Li; Xiao-Yan Wen; Esther Masih-Khan; Hong Chang; Jonathan B Pollett; Suzanne Trudel; A Keith Stewart
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

9.  Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

Authors:  Suzanne Trudel; Scott Ely; Yildiz Farooqi; Maurizio Affer; Davide F Robbiani; Marta Chesi; P Leif Bergsagel
Journal:  Blood       Date:  2004-01-08       Impact factor: 22.113

10.  K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.

Authors:  Patricia M-J Lievens; Alessandro Roncador; Elio Liboi
Journal:  J Mol Biol       Date:  2006-02-03       Impact factor: 5.469

View more
  56 in total

1.  Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation.

Authors:  Anette Bygum; Christina R Fagerberg; Ole J Clemmensen; Britta Fiebig; Christian Hafner
Journal:  BMC Med Genet       Date:  2011-06-05       Impact factor: 2.103

Review 2.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

3.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

4.  [R248C FGFR3 mutation. Effect on cell growth, apoptosis and attachment in HaCaT keratinocytes].

Authors:  C Hafner; A Hartmann
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

5.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.

Authors:  Christian Hafner; Agustí Toll; Alejandro Fernández-Casado; Julie Earl; Miriam Marqués; Francesco Acquadro; Marinela Méndez-Pertuz; Miguel Urioste; Núria Malats; Julie E Burns; Margaret A Knowles; Juan C Cigudosa; Arndt Hartmann; Thomas Vogt; Michael Landthaler; Ramón M Pujol; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 6.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

7.  Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.

Authors:  Christian Hafner; Elena López-Knowles; Nuno M Luis; Agustí Toll; Eulàlia Baselga; Alex Fernández-Casado; Silvia Hernández; Adriana Ribé; Thomas Mentzel; Robert Stoehr; Ferdinand Hofstaedter; Michael Landthaler; Thomas Vogt; Ramòn M Pujol; Arndt Hartmann; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-02       Impact factor: 11.205

Review 8.  Cutaneous mosaicism: right before our eyes.

Authors:  Jorge Frank; Rudolf Happle
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Disorders of phosphate homeostasis and tissue mineralisation.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Endocr Dev       Date:  2009-06-03

Review 10.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.